Equities

Jiangsu GDK Biotechnology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Jiangsu GDK Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)19.70
  • Today's Change-0.11 / -0.56%
  • Shares traded1.23m
  • 1 Year change+57.60%
  • Beta1.2441
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Jiangsu GDK Biotechnology Co Ltd is a China-based company principally engaged in the research, development, production, and sales of human vaccines. The Company’s products mainly include human vaccines for the prevention of infectious diseases such as influenza, rabies, chickenpox, shingles, and pneumonia. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)116.56m
  • Net income in CNY-126.51m
  • Incorporated2008
  • Employees452.00
  • Location
    Jiangsu GDK Biotechnology Co LtdNo. 12 Yujin RoadTAIZHOU 225300ChinaCHN
  • Phone+86 52 386205860
  • Fax+86 52 386200152
  • Websitehttp://www.gdkbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hunan Nucien Pharmaceutical Co Ltd119.87m-353.70m2.33bn360.00--2.69--19.44-1.28-1.280.43623.160.09981.410.4888---32.50-5.94-36.98-8.1932.4183.51-325.67-15.022.29-139.490.1562---64.64-23.64-9,613.65--35.48--
Shaanxi Kanghui Pharmaceutical Co Ltd513.23m-183.84m2.37bn906.00--3.27--4.62-1.84-1.845.147.260.26361.932.53566,479.70-11.36-1.99-18.19-2.6924.4636.16-43.08-6.590.5483-2.100.4726---16.545.42-242.62---10.54--
Jiangsu gdk Biotechnology Co Ltd116.56m-126.51m2.44bn452.00--2.05--20.94-1.03-1.030.94619.670.07750.73221.14257,878.40-8.421.65-9.842.1460.8073.17-108.547.561.83--0.046553.80-39.963.77-31.71--12.74--
Hangzhou Tianmushan Phrmtcl ntrprs C Ltd251.56m33.15m2.45bn362.0073.8636.78--9.740.27230.27232.070.54680.6322.972.32694,905.808.32-8.8427.42-25.8047.9332.1713.17-21.830.6559.230.648--78.44-6.06139.83-21.36-26.32--
Zhejiang East Asia Pharmaceutical Co Ltd831.56m-218.24m2.47bn1.75k--1.36--2.97-1.97-1.977.3415.800.24090.86345.60475,447.80-6.332.47-8.093.1225.7824.66-26.255.780.7513-411.460.353342.92-11.663.93-183.02--29.64--
Hainan Huluwa Pharmaceutical Grop Co Ltd902.48m-369.56m2.70bn2.10k--3.92--2.99-0.9236-0.92362.261.720.30551.741.60429,141.60-12.360.2178-22.130.373931.5354.80-40.470.32130.5566-6.970.6414700.10-21.261.60-2,629.23--21.75--
Zhejiang Shapuaisi Pharmaceutical Co Ltd475.19m-65.05m2.75bn1.33k--1.71--5.79-0.1796-0.17961.274.310.22362.3514.31357,822.00-3.08-2.12-3.66-2.4950.1155.38-13.78-7.330.8289-0.95060.1587---24.96-1.27-585.85--44.50--
Data as of Feb 13 2026. Currency figures normalised to Jiangsu GDK Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.02%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 202579.67k0.19%
Lion Fund Management Co., Ltd.as of 30 Jun 202575.00k0.18%
GF Fund Management Co., Ltd.as of 30 Jun 202565.85k0.15%
Penghua Fund Management Co., Ltd.as of 30 Jun 202539.63k0.09%
China Asset Management Co., Ltd.as of 30 Jun 202538.93k0.09%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202532.64k0.08%
Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 202532.50k0.08%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 202528.09k0.07%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 202522.33k0.05%
Bosera Asset Management Co., Ltd.as of 30 Jun 202521.97k0.05%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.